Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner tells Proactive it has met the necessary specifications and passed the final release tests for its first manufacturing run of REQORSA immunogene therapy in advance of non-small cell lung cancer (NSCLC) clinical trials.
Varner says the trials, Acclaim-1 and Acclaim-2, will evaluate REQORSA in combination with AstraZeneca’s drug Tagrisso and Merck & Co’s Keytruda, and both are on track to be initiated in the first half of the year.